Results 71 to 80 of about 5,159 (158)

Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships

ChemMedChem, Volume 21, Issue 1, January 2026.
Green chemistry‐based late‐stage functionalization (LSF) of the anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) early lead compound 5c led to optimized analogs with improved metabolic stability/PCSK9 IC50 ratio. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key drug target for the treatment of different hypercholesterolemia ...
Lisa Giannessi, Maria Giovanna Lupo, Martina Ugolotti, Bianca Papotti, Beatrice Mattina, Maria Grazia Martina, Anna Demurtas, Cristina Padula, Sara Nicoli, Marco Crescenzio, Nicola Ferri, Francesca Zimetti, Marco Radi   +12 more
wiley   +1 more source

Proprotein convertase subtilisin/kexin type 9 inhibitors protect against contrast-associated acute kidney injury in patients with atherosclerotic cardiovascular disease

Frontiers in Cardiovascular Medicine
Background and aimsContrast-associated acute kidney injury (CA-AKI) may occur in patients undergoing medical procedures involving x-rays and radiocontrast media, potentially resulting in prolonged renal impairment.
Yu Ma, Yu Ma, Hui Fan, Wei Mi, Jing Ma, Yong Deng, Yijie Song, Ximing Li, Ximing Li   +8 more
doaj   +1 more source

Astragalus membranaceus—Salvia miltiorrhiza Decoction Ameliorates Metabolic Syndrome and Gut Microbiota Dysbiosis Induced by High‐Fat Diet: A Comparative Study

Food Science &Nutrition, Volume 14, Issue 1, January 2026.
The optimal pairing ratio of ASDs against hyperlipidemia was systematically investigated. ASD maintains intestinal homeostasis and improves the systemic inflammatory response. A new LC–MS/MS method for the determination of derivatized SCFAs was established. ASD regulates the gut microbiota and its metabolites (SCFAs and BAs).
Haiyin Zhang, Haofang Wan, Yihang Lu, Yu He, Haitong Wan, Chang Li   +5 more
wiley   +1 more source

Retargeting the management of hypercholesterolemia – focus on evolocumab

, 2016
Alessandro Colletti,1 Giuseppe Derosa,2 Arrigo FG Cicero1 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, 2Department of Internal Medicine and Therapeutics, University of Pavia and Policlinico San Matteo Foundation, Pavia ...
Cicero, Arrigo Fg, CICERO, ARRIGO FRANCESCO GIUSEPPE, Derosa, G, Colletti A, Colletti, A, Colletti, Alessandro, DEROSA, GIUSEPPE, Derosa G, Cicero AFG   +8 more
core   +1 more source

Reduced Serum Soluble L‐Selectin Levels but Not PCSK9 May Be Associated With Generalized Anxiety Disorder: A Case–Control Study

Journal of Clinical Laboratory Analysis, Volume 40, Issue 1, January 2026.
The study included 88 generalized anxiety disorder (GAD) patients and 88 age and sex‐matched healthy controls (HCs). A psychiatrist confirmed the GAD diagnosis, assessed symptom severity using the GAD‐7 scale, and evaluated controls based on the DSM‐5 criteria.
Farzana Akter Munny, Abir Hasan Pranto, Shimanta Paul, Md. Aminul Haque, Rashna Sharmin, Sharifa Sultana, Md. Alamgir Hossain, Md. Rabiul Islam   +7 more
wiley   +1 more source

Profile of evolocumab and its potential in the treatment of hyperlipidemia

, 2015
Arrigo FG Cicero, Alessandro Colletti, Claudio Borghi Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy Abstract: Despite the proven efficacy of statins, they often fail to achieve low-density lipoprotein (LDL) cholesterol
Cicero AF, Borghi C, Colletti A
core  

Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely?

, 2015
Introduction: Statins alone often do not reduce LDL cholesterol levels sufficiently to given maximum cardiovascular benefit. Thus, additional drugs are required to reduce the levels of LDL cholesterol.
Doggrell, Sheila Anne, Lynch, Kaileen Anne   +1 more
core   +1 more source

Evolocumab-based LDL-C management in high and very high cardiovascular risk patients in German clinical practice : the HEYMANS study [PDF]

Introduction: Low-density lipoprotein cholesterol (LDL-C) is among the most important modifiable risk factors for cardiovascular disease. In very high-risk patients, the European Society of Cardiology/European Atherosclerosis Society guidelines ...
Fraass, Uwe, Tabbert-Zitzler, Anja, Dhalwani, Nafeesa N., Schettler, Volker, Lehrke, Michael, Vogt, Anja, Girndt, Matthias, Bridges, Ian, Ray, Kausik K.   +8 more
core   +2 more sources

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

, 2019
Chin-Chou Huang,1–5 Min-Ji Charng2,3 1Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; 2Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 3Faculty of Medicine, School
Huang CC, Charng MJ
core  

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence, Robinson, Jennifer G., Kastelein, John J.P., Roth, Eli M., Colhoun, Helen M., Pordy, Robert, Taskinen, Marja-Riitta, Ginsberg, Henry N., Kastelein, John J. P., Baccara-Dinet, Marie T.   +9 more
core   +1 more source